company background image
RSH

RespiriASX:RSH Stock Report

Market Cap

AU$49.2m

7D

3.0%

1Y

-67.6%

Updated

20 Oct, 2021

Data

Company Financials
RSH fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

RSH Overview

Respiri Limited, an e-health SaaS company, researches, develops, and commercializes medical devices in Australia and Israel.

Price History & Performance

Summary of all time highs, changes and price drops for Respiri
Historical stock prices
Current Share PriceAU$0.068
52 Week HighAU$0.061
52 Week LowAU$0.21
Beta-0.37
1 Month Change-6.85%
3 Month Change4.61%
1 Year Change-67.62%
3 Year Change-24.44%
5 Year Change36.00%
Change since IPO-94.15%

Recent News & Updates

Sep 21
Here's Why We're Watching Respiri's (ASX:RSH) Cash Burn Situation

Here's Why We're Watching Respiri's (ASX:RSH) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Jun 07
We Think Respiri (ASX:RSH) Can Afford To Drive Business Growth

We Think Respiri (ASX:RSH) Can Afford To Drive Business Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Shareholder Returns

RSHAU Medical EquipmentAU Market
7D3.0%3.0%1.7%
1Y-67.6%-6.5%20.2%

Return vs Industry: RSH underperformed the Australian Medical Equipment industry which returned -6.5% over the past year.

Return vs Market: RSH underperformed the Australian Market which returned 20.2% over the past year.

Price Volatility

Is RSH's price volatile compared to industry and market?
RSH volatility
RSH Beta-0.37
Industry Beta0.57
Market Beta1

Stable Share Price: RSH is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: RSH's weekly volatility (11%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
n/an/aMarjan Mikelhttps://respiri.co

Respiri Limited, an e-health SaaS company, researches, develops, and commercializes medical devices in Australia and Israel. The company develops, produces, and sells mobile health applications. Its products include Wheezo, an asthma management tool to help user understand their asthma by providing information, such as triggers, symptoms, medication usage, and other events.

Respiri Fundamentals Summary

How do Respiri's earnings and revenue compare to its market cap?
RSH fundamental statistics
Market CapAU$49.15m
Earnings (TTM)-AU$11.04m
Revenue (TTM)AU$1.39m

35.6x

P/S Ratio

-4.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
RSH income statement (TTM)
RevenueAU$1.39m
Cost of RevenueAU$1.26m
Gross ProfitAU$122.54k
ExpensesAU$11.16m
Earnings-AU$11.04m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.015
Gross Margin8.84%
Net Profit Margin-796.56%
Debt/Equity Ratio0%

How did RSH perform over the long term?

See historical performance and comparison

Valuation

Is Respiri undervalued compared to its fair value and its price relative to the market?

6.49x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate RSH's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate RSH's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: RSH is unprofitable, so we can't compare its PE Ratio to the Australian Medical Equipment industry average.

PE vs Market: RSH is unprofitable, so we can't compare its PE Ratio to the Australian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate RSH's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: RSH is overvalued based on its PB Ratio (6.5x) compared to the AU Medical Equipment industry average (5x).


Future Growth

How is Respiri forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

14.3%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Respiri has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Respiri performed over the past 5 years?

-32.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: RSH is currently unprofitable.

Growing Profit Margin: RSH is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: RSH is unprofitable, and losses have increased over the past 5 years at a rate of 32.2% per year.

Accelerating Growth: Unable to compare RSH's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: RSH is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (74.9%).


Return on Equity

High ROE: RSH has a negative Return on Equity (-145.84%), as it is currently unprofitable.


Financial Health

How is Respiri's financial position?


Financial Position Analysis

Short Term Liabilities: RSH's short term assets (A$8.9M) exceed its short term liabilities (A$1.5M).

Long Term Liabilities: RSH's short term assets (A$8.9M) exceed its long term liabilities (A$70.7K).


Debt to Equity History and Analysis

Debt Level: RSH's debt to equity ratio (0%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if RSH's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: RSH has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: RSH has sufficient cash runway for 1 years if free cash flow continues to reduce at historical rates of 13% each year.


Dividend

What is Respiri current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate RSH's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate RSH's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if RSH's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if RSH's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of RSH's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.9yrs

Average management tenure


CEO

Marjan Mikel

1.83yrs

Tenure

AU$1,556,111

Compensation

Mr. Marjan Mikel, M.Com, BSc (Hons), Dip Ed, MAICD), serves as Chief Executive Officer and Managing Director at Respiri Limited since December 2, 2019 and serves as its Executive Director since November 25...


CEO Compensation Analysis

Compensation vs Market: Marjan's total compensation ($USD1.16M) is above average for companies of similar size in the Australian market ($USD302.06K).

Compensation vs Earnings: Marjan's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: RSH's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.


Board Members

Experienced Board: RSH's board of directors are not considered experienced ( 1.9 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 10.7%.


Top Shareholders

Company Information

Respiri Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Respiri Limited
  • Ticker: RSH
  • Exchange: ASX
  • Founded: NaN
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: AU$49.153m
  • Shares outstanding: 722.84m
  • Website: https://respiri.co

Location

  • Respiri Limited
  • 432 St Kilda Road
  • Suite 1
  • Melbourne
  • Victoria
  • 3004
  • Australia

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/20 15:27
End of Day Share Price2021/10/20 00:00
Earnings2021/06/30
Annual Earnings2021/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.